Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 4/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.35 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 6/20 | 0.34 |
| ▸ | CCND1 | P24385 | 6/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15237004 | 0.93 | RIPK2 (0.37) | RIPK2ACVR1NOD2ERBB3EGFR | |
| SCHEMBL15035054 | 0.91 | CDK4 (0.36) | RIPK2ACVR1NOD2ERBB3EGFR | |
| SCHEMBL15041190 | 0.81 | RIPK2 (0.35) | RIPK2ACVR1NOD2EGFRCDK4 | |
| SCHEMBL15034947 | 0.81 | RIPK2 (0.36) | RIPK2ACVR1NOD2CDK4CCND1 | |
| SCHEMBL15035831 | 0.79 | PLK2 (0.39) | RIPK2ACVR1NOD2CDK4CCND1 | |
| SCHEMBL15035919 | 0.79 | CDK4 (0.35) | RIPK2ACVR1NOD2CDK4CCND1 | |
| SCHEMBL15035710 | 0.76 | CDK4 (0.35) | RIPK2ACVR1NOD2CDK4CCND1 | |
| SCHEMBL15035473 | 0.74 | CDK4 (0.41) | EGFRCDK4CCND1CCNA2CDK2 | |
| SCHEMBL15041193 | 0.73 | CAMK2D (0.41) | RIPK2ACVR1NOD2EGFRCDK4 | |
| SCHEMBL15035579 | 0.73 | CDK4 (0.39) | EGFRCDK4CCND1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | RIPK2 971/4885ACVR1 4752/4885NOD2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.